Table 3.

Localization of Foxp3+ cells (mammary)

Model	Treatment	Sample size (n)	Health status	Foxp3+ cells in lymph node	Foxp3+ cells in tumor periphery	Foxp3+ cells within tumor
FVB HER2/neu	-	8	Hh-free	68.3 ± 6.8 cells	17.8 ± 3.45 cells	0.2 ± 0.13 cells
HER2/neu sham	Sham IgG	6	Hh-free	nd	16.5 ± 2.75	0
HER2/neu +anti-TNF	Anti-TNF	6	Hh-free	46.4 ± 3.27	16.6 ± 4.47	5.4 ± 1.34
HER2/neu + sonicate	Hh sonicate (sterile)	10	Hh-free	39.5 ± 3.51	5.4 ± 1.18	1.10 ± 0.48

Cell counts between groups were compared using Mann–Whitney U analyses.

Foxp3+ lymph node (LN): p < 0.01; untreated (68.3 ± 6.8 cells) vs. anti-TNF-α (46.4 ± 3.27).

Foxp3+ in LN: p < 0.001; untreated (68.3 ± 6.8) vs. sterile Hh sonicate (39.5 ± 3.51).

Foxp3+ in tumor periphery: p < 0.001; untreated (17.8 ± 3.45) vs. Hh sonicate (5.4 ± 1.18).

Foxp3+ within tumor: p < 0.001; sham IgG (0 cells) vs. anti-TNF (5.4 ± 1.34).